Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Cancers × ridaforolimus × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 8 Neoplasm Metastasis 5 Sarcoma 4 Recurrence 4 Lymphoma 4 Endometrial Neoplasms 4 Breast Neoplasms 4 Ovarian Neoplasms 3 Solid Tumors 2 Prostatic Neoplasms 2 Multiple Myeloma 2 Carcinoma, Non-Small-Cell Lung 2 Solid Tumor 1 Primary Myelofibrosis 1 Osteosarcoma 1 Myelodysplastic Syndromes 1 Liposarcoma 1 Leukemia 1 Leiomyosarcoma 1 Hematologic Neoplasms 1 Glioblastoma 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1 Bone Neoplasms 1 Advanced Cancers 1

Interventions

Surveys and Questionnaires 5 pazopanib 3 Erlotinib Hydrochloride 3 Cetuximab 3 Vorinostat 2 Oxaliplatin 2 Bevacizumab 2 Azacitidine 2 satraplatin 1 ridaforolimus 1 ixazomib 1 X-Rays 1 Videotape Recording 1 Valproic Acid 1 Trastuzumab 1 Sugars 1 Sorafenib 1 Platinum 1 Pemetrexed 1 Magnetic Resonance Spectroscopy 1 Leucovorin 1 Lenalidomide 1 Lapatinib 1 LY 2275796 1 Injections, Subcutaneous 1 Fluorouracil 1 Everolimus 1 Curcumin 1 Crizotinib 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00836927 2019-02-18

MK-8669-038

Merck Sharp & Dohme LLC

Phase 2 Terminated

7 enrolled 13 charts

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon ⚡